Company News Summary | 16 Sep 2021

Click the print icon in your browser to print this report. Currency is in AUD unless otherwise specified

Australian Pharmaceutical Industries Announces Regarding Revised Non-Binding Indicative Proposal from Wesfarmers

10:02:00 | Associate analysts

Original annuncemenet:Revised Non-Binding Indicative Proposal from Wesfarmers

Australian Pharmaceutical Industries announced that it had received a non-binding indicative proposal from Wesfarmers to acquire 100% of the shares in the Company for cash consideration of $1.38 per share. This proposal was rejected by the Company Board on 29 July 2021. The Company announces that it has received a revised non-binding indicative proposal (Revised Indicative Proposal) from Wesfarmers to acquire 100% of the shares in the Company, by way of a scheme of arrangement, for cash consideration of $1.55 per share.

This report appeared on www.morningstar.com.au 2021 Morningstar Australasia Pty Limited

© Copyright 2021 Morningstar Australasia Pty Ltd ABN: 95 090 665 544 ("Morningstar"), AFSL no 240892. (a subsidiary of Morningstar, Inc.). This information is to be used for personal, non-commercial purposes only. No reproduction is permitted without the prior written content of Morningstar. Some of the material provided is published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO").

DISCLAIMER: To the extent that any of the content above constitutes advice, it is general advice that has been prepared without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain appropriate financial, legal and taxation advice before making any financial investment decision. If applicable, investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/About/ FSG or phone Morningstar on 1800 03 44 55 to request a copy. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for any use or distribution of any of this information

DISCLOSURE: Employees may have an interest in the securities discussed in this report.